We partner with healthcare and biotechnology companies to navigate critical moments by communicating the science, strategy, and value behind their innovation.
The new Russo Partners website is live. Explore our Insights hub, the Russo Edge Podcast, and how we work across media, IR, digital, and strategy to translate complex science into clear stories. https://t.co/awir7zKsKQ
#Biotech#LifeSciences#Healthcare#PR
$LCTX reported third quarter 2026 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update.
Learn more: https://t.co/1nov7I9Cl8
@CEO_Culley | #ReplaceAndRestore
After serving 20 years in the U.S. Army, including four combat deployments overseas, Dan Rathke never imagined that persistent heartburn would lead to a cancer diagnosis.
During his military service, Dan was exposed to burn pits in Iraq and Afghanistan and had a history of tobacco use. But it wasn't until 2023, when severe heartburn began waking him up at night, that he sought medical attention.
His primary care physician diagnosed him with GERD, a known risk factor for esophageal cancer, and recommended the EsoGuard® Test.
When his test results came back abnormal, Dan was referred to a gastroenterologist for an endoscopy. That's when doctors discovered very early-stage esophageal cancer.
Thankfully, the cancer was caught before it had spread and was successfully removed.
Dan's story is a powerful reminder of what early detection can make possible—and the important role primary care physicians play in identifying patients at risk.
This Veterans Day, we're honored to share Dan's story and thank him for his service. By speaking out, he hopes to encourage fellow veterans and others to understand their risk factors and talk with their healthcare providers about early detection.
Today, we announced that the U.S. FDA has granted Breakthrough Therapy designation to NVG-291 for the treatment of chronic traumatic cervical motor-incomplete spinal cord injury (SCI).
Read more: https://t.co/58Ems3TR6l
Too many promising drugs reach the market without knowing whether physicians and patients will adopt them.
On the Russo Edge, Harris Kaplan of Litmys explains to @SolomonsWisdom why safe and effective doesn’t always mean better, and how that gap inspired his new book, Approval Is Not Adoption.
▶️ Watch here: https://t.co/d8ohhN0fGT
🎙️ Apple Podcasts: https://t.co/lD1ofVjTRq
#Biotech #DrugDevelopment #Commercialization
Today, Ossium Health and @MyFranciscan announced the first reported bone marrow transplant using bone marrow from a deceased organ donor to treat a non-malignant disease.
Earlier this year, a patient with severe aplastic anemia received a transplant at Franciscan Health using bone marrow recovered from an organ donor and supplied by Ossium. Six months later, she has achieved durable engraftment and full donor chimerism, become independent of blood and platelet transfusions, and experienced no graft-versus-host disease (GVHD).
Why it matters: For non-malignant conditions like severe aplastic anemia, sickle cell disease, and beta thalassemia, bone marrow is the preferred graft source because it carries a lower risk of chronic GVHD. Yet most unrelated living donors give peripheral blood stem cells instead, leaving bone marrow in short supply. Organ donor bone marrow offers a way to expand access to this graft source without asking a living donor to undergo an invasive bone marrow harvest.
Read the full release: https://t.co/eeFqlGwpLQ
$COYA has announced 3Q26 financial results and provides a corporate update with the following highlights:
- Completed enrollment of 120 planned participants in the Phase 2/3 ALSTARS trial of COYA 302 for the treatment of ALS. Coya allowed participants in screening to enter the trial. A total of 137 participants were enrolled.
- In response to requests from ALSTARS investigators and study participants, Coya announced plans to initiate an open-label extension (OLE) of the ALSTARS trial, providing participants who complete the 48-week study period the opportunity to continue receiving COYA 302.
- Presented at the 2026 Annual NEALS Meeting Neurofilament Light Chain (NfL) Biomarker Stratification Methodology to Minimize the Impact of Heterogeneity in ALS Clinical Trials
- Announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences demonstrating complementary immunomodulatory effects in a well-established model of peripheral and central nervous system (CNS) inflammation.
Find more details here: https://t.co/Oy4m7aOhZx
A potential disease-modifying approach to Parkinson’s is showing early promise. In @Healio, Richard Gawel covers new Phase 1b data for Gain Therapeutics’ rexaceract, which showed stable motor function over a year of treatment. https://t.co/dJ1LTz7VFJ
#Parkinsons#Biotech
#NewsAlert: We are thrilled to welcome Aaron A. Ondrey to Syndax as our Chief Financial Officer.
Aaron brings decades of experience guiding biopharma companies through commercial expansion and major milestones. He will lead our financial strategy and organization as we scale our commercial business, advance our deep pipeline and deliver long-term shareholder value.
Learn more by reading our press release:
https://t.co/ChQR2apLex
What if patients could produce their own biologics? @BioCentury’s Danielle Golovin profiles Duracyte, a @RiceUniversity spinout building cell implants that secrete biologics in the body for up to a year. First trial expected in the first half of 2027.
https://t.co/Um4KC3LgAo
#Biotech #CellTherapy
.@ActuateThera has received a U.S. Notice of Allowance for a patent covering oral tablet forms of investigational elraglusib, its GSK-3β inhibitor, ahead of a planned Phase 1/2 trial of the Elraglusib Oral Tablet in Q1 2027. $ACTU
Read more: https://t.co/IChyFpW7dz
$LCTX announced it will report Q3 2026 financial and operating results on Thursday, November 12, 2026. Management will host a conference call at 4:30 p.m. ET/ 1:30 p.m. PT to provide a business update.
For more: https://t.co/NcwWiKq3Q3
#ReplaceAndRestore
Largest real-world study of nonendoscopic esophageal precancer testing to date, now peer-reviewed in @diagnostic_mdpi
11,991 patients tested with EsoGuard® via EsoCheck®:
• 95% collection success
• Under 2 minutes average collection time
• 96% would recommend it
Details: https://t.co/QB4jE3n5uy
Proud to share that @Forbes has featured Ossium Health as today's Daily Cover story.
@amyfeldman's piece tells the story behind the world's first bone marrow bank. Today, Ossium's bone marrow from deceased donors is being used in dozens of transplants for malignant and non-malignant blood diseases, and the story looks ahead to commercial availability for thousands more patients and the conditions Ossium hopes to explore next.
None of it happens without the donors and their families, the organ procurement organizations, and the transplant centers. Thank you for the work you do every day.
Read the full story: https://t.co/Kk839DRnDw
@KevinCaldweII@firstround@generalcatalyst@huntsmancancer@UofUHealth@MyFranciscan@GiftofLifeMich@LifeGift
Spinal cord injury isn’t rare, but no two cases look alike. Former @US_FDA acting commissioner Dr. Janet Woodcock tells @PharmaPinkSheet the field needs rare-disease-style regulatory flexibility. https://t.co/sa3lnmAWeb
#SCI
#NewsAlert: Today, we reported our third quarter 2026 financial results and provided a business update.
We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax.
With growing revenue from two medicines, a robust pipeline generating multiple blockbuster opportunities, world-class R&D capabilities, and a strong balance sheet, Syndax is poised to deliver long-term value.
Learn more by reading our press release and joining our conference call today at 4:30 p.m. ET:
https://t.co/qgYWt8YUAj
A live replay will be available after the call for a limited time.
$LCTX’s @CEO_Culley is looking forward to joining Ben Beneski, SVP & CTO of @AllogeneTx, on the next live @_CellandGenewebinar, moderated by @Erin_Harris1 to discuss the requirements for #celltherapy late-stage development and commercialization.
Register to watch on 11/12 here: https://t.co/cA87bloF7U
#CellTherapy #GeneTherapy #RegenerativeMedicine #ReplaceandRestore
Spinal cord injury drugs may need a different kind of clinical trial. In @Citeline’s In Vivo, Bridget Silverman speaks with former @FDA chief Janet Woodcock on why the condition calls for more flexible, patient-centered endpoints.
https://t.co/d3rO1xgHMK
#SpinalCordInjury#FDA